The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

Giacomelli, Roberto; Afeltra, Antonella; Bartoloni, Elena; Berardicurti, Onorina; Bombardieri, Michèle; Bortoluzzi, Alessandra; Carubbi, Francesco; Caso, Francesco; Cervera, Ricard; Ciccia, Francesco; Cipriani, Paola; Coloma, Emmanuel; Conti, Fabrizio; Costa, Luisa; D’Angelo, Salvatore; Distler, Oliver; Feist, Eugen; Gabini, Marco; Gerber, V. Ya.; Gerli, Roberto; Grembiale, Rosa Daniela; Guggino, Giuliana; Hoxha, Ariela; Iagnocco, Annamaria; Jordan, Suzana; Kahaleh, Bashar; Lauper, Kim; Liakouli, Vasiliki; Lubrano, Ennio; Margiotta, Domenico Paolo Emanuele; Naty, Saverio; Navarini, Luca; Perosa, Federico; Perricone, Carlo; Perricone, Roberto; Prete, Marcella; Pers, Jacques‐Olivier; Pitzalis, Costantino; Priori, Roberta; Rivellese, Felice; Ruffatti, Amelia; Ruscitti, Piero; Scarpa, Raffaele; Shoenfeld, Yehuda; Triolo, Giovanni; Tzioufas, Athanasios G.

doi:10.1016/j.autrev.2020.102738

Cited by 48 publications

(29 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mSGB is a cornerstone in pSS diagnosis, but to date, its role is underestimated in the follow-up of pSS patients, and behind its valuable role in pSS classification criteria, its potential use in different clinimetric settings is still poorly recognized. Our SLR pointed out the limited number of studies that explored the association between histologic scores and pSS clinical presentation and prognosis, confirming what was already reported (28,29). Furthermore, in the analyzed studies, different standards and different definitions were used to evaluate the results of mSGBs and any study that independently selected the clinical features of disease presentation, making challenging the comparison of the results and the quantitative analysis.…”

Section: Discussionsupporting

confidence: 80%

Association Between Minor Salivary Gland Biopsy During Sjӧgren’s Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

ObjectivePatients with primary Sjögren’s syndrome (pSS) may develop a potentially severe disease with extra-glandular involvement and lymphoma insurgence. Minor salivary gland biopsy is routinely used in the disease diagnosis, but its potential role as a biomarker for clinical disease presentation and prognosis is still poorly understood.MethodsWe performed a systematic review and meta-analysis on clinical presentation and prognosis in pSS patients who underwent minor salivary gland biopsy at diagnosis according to the PRISMA guidelines.ResultsWe included five retrospective studies and 589 pSS patients. Ectopic GCs presence was not associated with a significant increase in the odds ratio for the clinical variables explored such as salivary gland swelling, arthritis, and Raynaud’s phenomenon. As far as serological features are concerned, ectopic GCs presence accounted for an increased ratio of antibodies anti-SSA (OR = 3.13, 95% CI: 1.25–7.85, p = 0.02, I2 = 79%), anti-SSB (OR = 3.94, 95% CI: 1.50–10.37, p = 0.0005, I2 = 80%), and RFs presence (OR = 3.12, 95% CI: 1.94–5.00, p < 0.00001, I2 = 0%).ConclusionsThis study showed that the association between ectopic GC in salivary glands identifies a clinical subset characterized by autoantibodies presence, and probably pSS patients affected from a more severe disease.

show abstract

Section: Discussionsupporting

confidence: 80%

Association Between Minor Salivary Gland Biopsy During Sjӧgren’s Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nowadays, precision medicine is becoming more common in the management of diseases. It takes into account the individual characteristics of each patient to tailor therapeutic strategies that are applied (right treatment, personalized timing of drug administration) to maximize drug efficacy, and if possible, reduce AEs [58][59][60]. In this context, the development of alternative strategies is of prime interest.…”

Section: Current Treatmentsmentioning

confidence: 99%

CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention

Brun

Sèze

Muller

2022

Immuno

View full text Add to dashboard Cite

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system. This clinically heterogeneous neurological disorder is closely related to Guillain–Barré syndrome and is considered the chronic counterpart of that acute disease. Currently available treatments are mostly empirical; they include corticosteroids, intravenous immunoglobulins, plasma exchange and chronic immunosuppressive agents, either alone or in combination. Recent advances in the understanding of the underlying pathogenic mechanisms in CIDP have brought a number of novel ways of possible intervention for use in CIDP. This review summarizes selected pre-clinical and clinical findings, highlights the importance of using adapted animal models to evaluate the efficacy of novel treatments, and proposes the outlines of future directions to ameliorate the conditions of patients with CIDP.

show abstract

“…High Body Mass Index (BMI) is common (> 60%) among patients with RA [30], and it is associated with higher disease activity and disability [31,32]. The impact of obesity on the effectiveness of bDMARDs appears to vary between drug classes [33].…”

Section: Obesitymentioning

confidence: 99%

Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

Tsuchiya

Fujio

2021

IJMS

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease characterized by destructive synovitis. It is significantly associated with disability, impaired quality of life, and premature mortality. Recently, the development of biological agents (including tumor necrosis factor-α and interleukin-6 receptor inhibitors) and Janus kinase inhibitors have advanced the treatment of RA; however, it is still difficult to predict which drug will be effective for each patient. To break away from the current therapeutic approaches that could be described as a “lottery,” there is an urgent need to establish biomarkers that stratify patients in terms of expected therapeutic responsiveness. This review deals with recent progress from multi-faceted analyses of the synovial tissue in RA, which is now bringing new insights into diverse features at both the cellular and molecular levels and their potential links with particular clinical phenotypes.

show abstract

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

Cited by 48 publications

References 171 publications

Association Between Minor Salivary Gland Biopsy During Sjӧgren’s Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis

Association Between Minor Salivary Gland Biopsy During Sjӧgren’s Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis

CIDP: Current Treatments and Identification of Targets for Future Specific Therapeutic Intervention

Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About